Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Structurally-modified antibody – immunoglobulin – or fragment...
Reexamination Certificate
2002-02-01
2003-11-25
Chan, Christina (Department: 1644)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Structurally-modified antibody, immunoglobulin, or fragment...
C424S144100, C424S173100, C424S143100
Reexamination Certificate
active
06652856
ABSTRACT:
FIELD OF THE INVENTION
This invention relates to methods for treating fibrosis in subjects in need of such treatment.
BACKGROUND OF THE INVENTION
Collagen is a fibril-forming protein which is essential for maintaining the integrity of the extracellular matrix found in connective tissues. The production of collagen is a highly regulated process, and its disturbance may lead to the development of tissue fibrosis. While the formation of fibrous tissue is part of the normal beneficial process of healing after injury, in some circumstances there is an abnormal accumulation of fibrous materials such that it may ultimately lead to organ failure (Border et al. (1994)
New Engl. J. Med.
331:1286-1292). Injury to any organ leads to a stereotypical physiological response: platelet-induced hemostasis, followed by an influx of inflammatory cells and activated fibroblasts. Cytokines derived from these cell types drive the formation of new extracellular matrix and blood vessels (granulation tissue). The generation of granulation tissue is a carefully orchestrated program in which the expression of protease inhibitors and extracellular matrix proteins is upregulated, and the expression of proteases is reduced, leading to the accumulation of extracellular matrix.
Central to the development of fibrotic conditions, whether induced or spontaneous, is stimulation of fibroblast activity. The influx of inflammatory cells and activated fibroblasts into the injured organ depends on the ability of these cell types to interact with the interstitial matrix, which contains primarily collagens. The major cell surface collagen receptors are the &agr;1&bgr;1 (VLA-1) and &agr;2&bgr;1 (VLA-2) integrins. Both integrins have been implicated in cell adhesion and migration on collagen (Keely et al. (1995)
J. Cell Sci.
108:595-607 and Gotwals et al. (1996)
J. Clin. Invest.
97: 2469-2477); in promoting contraction of collagen matrices (Gotwals et al. (1996)
J. Clin. Invest.
97: 2469-2477 and Schiro, (1991)
Cell
67:403-410), and in regulating the expression of genes involved in the remodeling of the extracellular matrix (Riikonen et al. (1995)
J. Biol. Chem.
270:1-5 and Langholz et al. (1995)
J. Cell Biol.
131: 1903-1915). For example, when fibroblasts contact a collagen matrix, signaling through the &agr;1&bgr;1 integrin down-regulates collagen I expression, while signaling through &agr;2&bgr;1 up-regulates the expression of matrix metalloproteases (Langholz et al. (1995)
J. Cell Biol.
131: 1903-1915).
Many of the diseases associated with the proliferation of fibrous tissue are both chronic and often debilitating, including for example, skin diseases such as scleroderma. Some, including pulmonary fibrosis, can be fatal due in part to the fact that the currently available treatments for this disease have significant side effects and are generally not efficacious in slowing or halting the progression of fibrosis (Nagler et al. 1996,
Am. J. Respir. Crit. Care Med.,
154:1082-86).
There is, accordingly, a continuing need for new anti-fibrotic agents.
In contrast to the trends in research in the field of anti-fibrotic therapy which has focused on upstream cytokine mediators of fibrosis, such as TGF-&bgr;, we propose the use of antibody molecules comprising antigen binding regions derived from the heavy or light chain variable regions of an anti-VLA antibody, for use in anti-fibrotic treatment and specifically for treatment of pulmonary fibrosis.
SUMMARY OF THE INVENTION
The present invention provides a method of treating fibrosis in a subject. Specifically, the invention provides a method for treating fibrosis by administering to a patient a pharmaceutical composition containing an effective amount of an antibody molecule having antigen binding regions derived from the light and heavy chain variable regions of an anti-VLA antibody. In a preferred embodiment, the anti-VLA antibody is anti-VLA-1, -2, -3, -4, -5, and -6. In a most preferred embodiment, the invention provides a method for treating pulmonary fibrosis by administering to a patient a pharmaceutical composition containing an effective amount of an antibody molecule having antigen binding regions derived from the light and heavy chain variable regions of an anti-VLA-1 and anti-VLA-2 antibody.
The anti-VLA antibody can be selected from the group consisting of a human antibody, a chimeric antibody, a humanized antibody and fragments thereof. The anti-VLA antibody can be a monoclonal or polyclonal antibody.
The invention further provides a method for treating fibrosis in a subject that is a human or animal subject.
All of the cited literature in the preceding section, as well as the cited literature included in the following disclosure, are hereby incorporated by reference.
REFERENCES:
patent: 4683195 (1987-07-01), Mullis et al.
patent: 5789650 (1998-08-01), Lonberg et al.
patent: 5798230 (1998-08-01), Bornkamm et al.
patent: 0239400 (1997-09-01), None
patent: WO 90/07861 (1990-07-01), None
patent: WO9313798 (1993-07-01), None
patent: WO94 17828 (1994-09-01), None
patent: WO95 19790 (1995-07-01), None
patent: WO97 11718 (1997-04-01), None
patent: WO97 18838 (1997-05-01), None
shock et al., In Adhesion Molecules and the lung. Eds P. Ward and J. Fantone, Marcel Dekker, Inc., New Yrk, Chapter 8, pp. 177-209, 1996.*
Humphries MJ. Integrin cell adhesion receptors and the concept of agonism. Trends Pharmacol Sci. 21(1):29-32, 2000.*
Baldwin et al., 1998, Structure, 6:923-935, “Cation binding to the integrin CD11b I domain and activation model assessment”.
Bennett et al., 1983, Proc. Natl. Acad. Sci., 80:2417-2421, “Inhibition of fibrinogen binding to stimulated human platelets by a monoclonal antibody”.
Boerner et al., 1991, J. Immunol., 147:86-95, “Production of Antigen-Specific Human Monoclonal Antibodies From In Vitro-Primed Human Splenocytes”.
Border et al., 1994, New England J. Medicine, 331:1286-1292, “Transforming Growth Factor Beta In Tissue Fibrosis”.
Bossy et al., 1991, EMBO J., 10:2375-2385, “Characterization of the integrin Alpha8 subnit: A new intefrin beta1-associated subunit, which is prominently expressed on axons and on cells in contact with basal laminae in chick embryos”.
Briesewitz et al., 1993, J. of Biol. Chemistry, 268:2989-2996, “Expression of Native and Truncated Forms of the human integrin Alpha1 1 subunit*”.
Bridges et al., 1995, Mol. Immunol., 32:1329-2989, “Variable Region cDNA Sequences and Characterization of Murine Anti-Human Interferon y Receptor Monoclonal Antibodies that Inhibit Receptor Binding By Interferon y”.
Camper et al., 1998, J. Biol. Chem., 273:20383-20389, “Isolation, Cloning, and Sequence Analysis of the Integrin Subunit a10, a Beta1-associated Collagen Binding Integrin Expressed on Chondrocytes*”.
Cerf-Bensussan et al., 1992, Eur. J. Immunol. 22:273-277, “The human intraepithelial lymphocyte marker HML-1 is an integrin consisting of a Beta7 subunit associated with a distinctive alpha chain”.
Clackson et al., 1991, Nature, 352:624-628, “Making antibody fragments using phage display libraries”.
Co et al., 1991, Proc. Natl Acad. Sci., 88:2869-2873, “Humanized anotbodies for antiviral therapy”.
Colbert et al, 1991, J. of Immunol. Methods, 140: 227-233, “The effect of fluorescein labels on the affinity of antisera to small haptens”.
Corbi and Miller et al., 1987, J. of Biol. Chem. 263: 12403-12411, “cDNA cloning and complete primary struction fo the alpha subunit of a leukocyte adhesion glycoprotein, p150,95”.
Corbi and Kishimoto et al., 1988, J. of Biol. Chem., 263: 12403-12411, “The Human Leukocyte Adhesion Glycoprotein Mac-1 (Complement Receptor Type 3, CD11b) alpha Subunit”.
Davies, 1989, J. of Cell Biology, 109: 1817-1826, “The Osteoclast Functional Antigen, Implicated in the Regulation of Bone Resorption, Is Biochemically Related to the Vitronectin Receptor”.
Diamond et al., 1993, 120: 1031-1043, “The I Domain Is a Major Recognition Site on the Luekocyte Intgegrin Mac-1 (CD-11b/CD18) For Four Distinct Adhesion Ligands”.
Edwards et al., 1995, 270:12635-12640, “Identification of Amino Acids in the CD11a I-do
Gotwals Philip J.
Kotelianski Victor
Biogen Inc.
Chan Christina
Haddad Maher
LandOfFree
Method for the treatment of fibrosis does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for the treatment of fibrosis, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for the treatment of fibrosis will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3140583